Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138563 | 1.00 | LCAT (0.59) | LCATMAPTCYP2C9CYP2C19GAA | |
| SCHEMBL18138565 | 1.00 | LCAT (0.59) | LCATMAPTCYP2C9CYP2C19GAA | |
| SCHEMBL19485089 | 0.91 | LCAT (0.50) | LCATMAPTCYP2C9CYP2C19GAA | |
| SCHEMBL18138496 | 0.86 | LCAT (0.59) | LCAT | |
| SCHEMBL18138494 | 0.86 | LCAT (0.59) | LCAT | |
| SCHEMBL18138503 | 0.86 | LCAT (0.59) | LCAT | |
| SCHEMBL18138507 | 0.86 | LCAT (0.59) | LCAT | |
| SCHEMBL18138495 | 0.86 | LCAT (0.59) | LCAT | |
| SCHEMBL18138629 | 0.84 | LCAT (0.59) | LCAT | |
| SCHEMBL18138630 | 0.84 | LCAT (0.59) | LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081566-B1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9796709-B2 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-9796709-B2 | 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-29 | — | — | US | disclosed |
| EP-3081566-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376267-A1 | 5-HYDROXY-4-(TRIFLUOROMETHYL)PYRAZOLOPYRIDINE DERIVATIVE | LDLR, LCAT, LPL | LCAT 2/4885MAPT 984/4885CYP2C9 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.